<code id='241F35D415'></code><style id='241F35D415'></style>
    • <acronym id='241F35D415'></acronym>
      <center id='241F35D415'><center id='241F35D415'><tfoot id='241F35D415'></tfoot></center><abbr id='241F35D415'><dir id='241F35D415'><tfoot id='241F35D415'></tfoot><noframes id='241F35D415'>

    • <optgroup id='241F35D415'><strike id='241F35D415'><sup id='241F35D415'></sup></strike><code id='241F35D415'></code></optgroup>
        1. <b id='241F35D415'><label id='241F35D415'><select id='241F35D415'><dt id='241F35D415'><span id='241F35D415'></span></dt></select></label></b><u id='241F35D415'></u>
          <i id='241F35D415'><strike id='241F35D415'><tt id='241F35D415'><pre id='241F35D415'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:847
          Christine Kao/STAT

          After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra Collins did what many freshly minted Ph.D.s. do — she went looking for a job at a biotech company. But what was supposed to be a straightforward search has turned into an odyssey.

          Collins has applied for more than 53 positions (and counting). Like a good scientist, she’s gathering data along the way and uses a spreadsheet to track each company’s size and therapeutic focus, as well as whether she was referred for the position and how far she made it through the application process. So far, those efforts have been unsuccessful.

          advertisement

          “I try my best not to take it personally. These are companies that are trying to find an employee who’s going to help them achieve their business goals,” Collins said. “But it is pretty discouraging just repeatedly getting turned down, especially at later stages of the interview process.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Designating disabled people as health disparity population is crucial

          AdobeMydaughterKatiewasbornwithseveredisabilities.Shewentontodevelopprofoundautism,attentiondeficitd